|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-2-21
|
|
pubmed:abstractText |
Identification of tumor antigens and their optimal antigenic peptides raised hopes for the development of peptide-based immunotherapeutic vaccine strategies for human melanoma, however. Synthetic peptides alone are not immunogenic enough, and adequate formulation is critical for elaboration of peptide vaccines. To improve formulation, we evaluated 2 lipopeptide constructs, both including HLA-A2-restricted MART 27-35-CD8+ T lymphocyte (CTL) epitope covalently linked to universal tetanus toxoid (TT) 830-843 helper T lymphocyte (HTL) epitope, in HLA-A2 transgenic mouse models that mimic human CTL responses in vivo. These 2 constructs only differed in the formulation of their lipid tail. We showed that lipopeptide constructs were strongly recognized, in vitro, by human MART 27-35 cytotoxic T cells derived from tumor-infiltrating lymphocytes. The transgenic Mice immunized with these 2 MART lipopeptide formulations containing covalently linked HTL-CTL epitopes induced strong MART 27-35 cytotoxic T cells. This CTL induction was critically dependent on the presence of the helper T lymphocyte epitope. These results also showed that a single palmitoyl-lysine chain is enough to assure immunogenicity of a given peptide and that the presence of a lipid tail bypass the need for adjuvant. These results support the selection of MART-lipopeptide melanoma vaccine for evaluation in a clinical trial.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/MART-1-Melan-A(27-35) epitope,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Tetanus Toxoid,
http://linkedlifedata.com/resource/pubmed/chemical/tetanus toxoid (830-843)
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0020-7136
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
221-7
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11857412-Adjuvants, Immunologic,
pubmed-meshheading:11857412-Amino Acid Sequence,
pubmed-meshheading:11857412-Animals,
pubmed-meshheading:11857412-Cancer Vaccines,
pubmed-meshheading:11857412-Cell Line,
pubmed-meshheading:11857412-Cells, Cultured,
pubmed-meshheading:11857412-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:11857412-Epitopes,
pubmed-meshheading:11857412-HLA-A2 Antigen,
pubmed-meshheading:11857412-Lipoproteins,
pubmed-meshheading:11857412-Melanoma, Experimental,
pubmed-meshheading:11857412-Mice,
pubmed-meshheading:11857412-Mice, Transgenic,
pubmed-meshheading:11857412-Neoplasm Proteins,
pubmed-meshheading:11857412-Peptide Fragments,
pubmed-meshheading:11857412-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11857412-T-Lymphocytes, Helper-Inducer,
pubmed-meshheading:11857412-Tetanus Toxoid,
pubmed-meshheading:11857412-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
|
|
pubmed:affiliation |
Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM unité 445, I.C.G.M., Université R.Descartes, Hôpital Cochin, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
